Contineum Therapeutics (CTNM) Research & Development (2023 - 2026)

Contineum Therapeutics' Research & Development history runs 4 years deep, the most recent figure standing at $11.6 million for Q1 2026.

• In Q1 2026, Research & Development fell 15.05% year-over-year to $11.6 million; the TTM figure through Mar 2026 stood at $49.5 million (up 11.5% YoY), while the FY2025 annual figure was $51.5 million, up 34.1% from the prior year.
• Research & Development was $11.6 million for Q1 2026 at Contineum Therapeutics, down from $12.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $14.1 million in Q2 2025 to a low of $3.6 million in Q1 2023.
• Historically, Research & Development has averaged $9.9 million across 4 years, with a median of $9.7 million in 2024.
• Biggest YoY gain for Research & Development was 114.15% in 2024; the steepest drop was 16.48% in 2024.
• A 4-year view of Research & Development shows it stood at $8.0 million in 2023, then soared by 62.44% to $13.0 million in 2024, then fell by 2.0% to $12.8 million in 2025, then dropped by 8.68% to $11.6 million in 2026.
• The last three Research & Development figures came in at $11.6 million (Q1 2026), $12.8 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.